- Company
- Adempas’s nears reimb nearly 10 years after approval
- by Eo, Yun-Ho Mar 25, 2025 05:54am
- The reimbursement of the pulmonary arterial hypertension drug 'Adempas' is near in Korea, 10 years after its approval. The National Health Insurance Service is currently negotiating with Bayer Korea for its Adempas (riociguat). However, the negotiations are expected to be concluded and the drug listed soon. The negotiations for Adempas
- Company
- HLB shares plummet upon 2nd FDA rejection of rivoceranib
- by Cha, Jihyun Mar 25, 2025 05:54am
- The shares of HLB Group affiliates plummeted as HLB's new drug for liver cancer failed to enter the US market again. The total market capitalization of HLB Group stocks evaporated by over KRW 3 trillion in a single day. However, this did not cause a simultaneous drop in domestic bio stocks. HLB Group's 10 listed affiliates evaporate by KR
- Company
- The first RSV vaccine 'Arexvy' to launch in May in Korea
- by Whang, byung-woo Mar 25, 2025 05:54am
- As the launching date of Arexvy, known as the first respiratory syncytial virus vaccine, has been announced, the company aims to challenge a market share. According to industry sources on March 22, GSK Korea has confirmed the launching date of the RSV-LRTD vaccine, Arexvy, as May. Arexvy received approval from the Ministry of Food and D
- Company
- 'Xeljanz' reimbursed for juvenile idiopathic arthritis
- by Eo, Yun-Ho Mar 24, 2025 05:52am
- 'Xeljanz' has become the first JAK inhibitor to be reimbursed for the treatment of juvenile idiopathic arthritis. The Ministry of Health and Welfare (MOHW) has recently announced on the administrative notification board regarding the 'The Criteria and Scope of National Health Insurance (Pharmaceuticals)' that the reimbursement criteria fo
- Company
- RSV vaccine Beyfortus lands in Big 5 Hospitals in Korea
- by Eo, Yun-Ho Mar 24, 2025 05:52am
- The respiratory syncytial virus (RSV) preventive antibody injection ‘Beyfortus’ has landed in the Big 5 tertiary hospitals in Korea. According to industry sources, Sanofi Korea's Beyfortus (nirsevimab) has passed the drug committees (DCs) of the Big 5 tertiary hospitals in Korea, including Samsung Medical Center, Seoul National Universi
- Company
- Bispecific multiple myeloma drug 'Talvey' can be prescribed
- by Eo, Yun-Ho Mar 21, 2025 06:00am
- New bispecific multiple myeloma drug 'Talvey' can now be prescribed at general hospitals. According to industry sources, Janssen Korea's Talvey (talquetamab) has passed the drug committees (DC) of tertiary general hospitals, including Samsung Medical Center and Seoul National Univeristy Hospital, and medical institutes, including Pusan Na
- Company
- Prevnar 20 added to the National Immunization Program
- by Whang, byung-woo Mar 21, 2025 05:59am
- Pfizer is signaling full-fledged competition with the addition of its new pneumococcal vaccine, Prevnar 20, to the National Immunization Program (NIP) for children. According to industry sources on the 21st, the Korea Disease Control and Prevention Agency recently reviewed the introduction of PCV20 NIP for children during the 1st Korea Exp
- Company
- "Leclaza combo improves survival than Tagrisso monotherapy"
- by Son, Hyung Min Mar 21, 2025 05:58am
- It has been reported that the Leclaza plus Rybrevant combination therapy demonstrated improved overall survival (OS), in addition to progression-free survival (PFS), than Tagrisso. According to industry sources on March 20, the European Society for Medical Oncology made abstracts available for the 'European Lung Cancer Congress 2025(ELC
- Company
- Hanmi and Samsung Bioepis join forces to sell Prolia similar
- by Cha, Jihyun Mar 20, 2025 06:01am
- Hanmi Pharmaceutical and Samsung Bioepis announced on the 19th that they had signed a joint sales agreement on the 18th for the domestic launch of the osteoporosis treatment Prolia biosimilar (Project name: SB16, ingredient name: denosumab) in Korea. Under the agreement, Samsung Bioepis is responsible for the production and supply of the
- Company
- Will COVID-19 vaccines be added to the NIP this year?
- by Whang, byung-woo Mar 20, 2025 06:00am
- As the government began the process of reviewing the inclusion of COVID-19 vaccines in the National Immunization Program (NIP) list, attention has been drawn to whether COVID-19 would be included in the NIP list within this year. According to industry sources on March 20, the Korea Disease Control and Prevention Agency (KDCA) and major pha
